BB Biotech AG

BION:SWX

BB Biotech AG

Actions
  • Price (CHF)36.25
  • Today's Change0.300 / 0.83%
  • Shares traded37.79k
  • 1 Year change-6.93%
  • Beta1.0985
Data delayed at least 15 minutes, as of Nov 22 2024 13:47 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CHF
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,9352,3532,944
Total Receivables, Net1.83--0
Total Inventory------
Prepaid expenses------
Other current assets, total700700700
Total current assets2,6373,0533,644
Property, plant & equipment, net------
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets2,6373,0533,644
LIABILITIES
Accounts payable5.44--0
Accrued expenses------
Notes payable/short-term debt305363355
Current portion long-term debt/capital leases------
Other current liabilities, total3.604.255.59
Total current liabilities314367361
Total long term debt000
Total debt305363355
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities314367361
SHAREHOLDERS EQUITY
Common stock111111
Additional paid-in capital------
Retained earnings (accumulated deficit)2,3492,7123,282
Treasury stock - common(37)(37)(9.21)
Unrealized gain (loss)------
Other equity, total------
Total equity2,3232,6863,283
Total liabilities & shareholders' equity2,6373,0533,644
Total common shares outstanding555555
Treasury shares - common primary issue0.550.550.11
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.